These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15581455)

  • 1. [PCSK9: a new gene involved in familial hypercholesteremia].
    Lambert G; Costet P; Krempf M; Lalanne F
    Med Sci (Paris); 2004 Dec; 20(12):1068-70. PubMed ID: 15581455
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent advances in familial hypercholesterolemia].
    Bruckert E
    Ann Endocrinol (Paris); 2007 Jun; 68(2-3):97. PubMed ID: 17512894
    [No Abstract]   [Full Text] [Related]  

  • 3. The mystery of PCSK9.
    Attie AD
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1337-9. PubMed ID: 15297287
    [No Abstract]   [Full Text] [Related]  

  • 4. Beyond LDL cholesterol, a new role for PCSK9.
    Akram ON; Bernier A; Petrides F; Wong G; Lambert G
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia.
    Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What promise does PCSK9 hold?
    Kastelein JJ; Fouchier SW; Defesche JC
    J Am Coll Cardiol; 2005 May; 45(10):1620-1. PubMed ID: 15893177
    [No Abstract]   [Full Text] [Related]  

  • 7. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K; Chetiveaux M; Zair Y; Costet P; Abifadel M; Varret M; Boileau C; Magot T; Krempf M
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1448-53. PubMed ID: 15166014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility gene card for: hyperlipoproteinemia, TYPE II.
    Kassner U; Wühle-Demuth M; Missala I; Humphries SE; Steinhagen-Thiessen E; Demuth I
    Eur J Hum Genet; 2014 Jul; 22(7):. PubMed ID: 24253857
    [No Abstract]   [Full Text] [Related]  

  • 9. Protease variants, LDL, and coronary heart disease.
    Tall AR
    N Engl J Med; 2006 Mar; 354(12):1310-2. PubMed ID: 16554535
    [No Abstract]   [Full Text] [Related]  

  • 10. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
    J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of the first PCSK9 gain of function homozygote.
    Alves AC; Etxebarria A; Medeiros AM; Benito-Vicente A; Thedrez A; Passard M; Croyal M; Martin C; Lambert G; Bourbon M
    J Am Coll Cardiol; 2015 Nov; 66(19):2152-2154. PubMed ID: 26541928
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
    Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G
    Atherosclerosis; 2008 Feb; 196(2):659-66. PubMed ID: 17765244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorting the wheat from the chaff in familial hypercholesterolemia.
    Hooper AJ; Watts GF
    Clin Chem; 2015 Jan; 61(1):6-8. PubMed ID: 25391991
    [No Abstract]   [Full Text] [Related]  

  • 14. [PCSK9 inhibitor is convincing a large analysis].
    Schlimpert V
    MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
    [No Abstract]   [Full Text] [Related]  

  • 15. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
    Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR
    Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
    Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
    Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?
    Jirholt P; Adiels M; Borén J
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1334-6. PubMed ID: 15297286
    [No Abstract]   [Full Text] [Related]  

  • 18. [Molecular basis of familial hypercholesterolemia-like phenotype heterogeneity].
    Wang LY; Lin J; Liu S; Chen BS
    Yi Chuan Xue Bao; 2005 Jul; 32(7):770-7. PubMed ID: 16078748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein receptor activity in Epstein-Barr virus-transformed lymphocytes from heterozygotes for the D374Y mutation in the PCSK9 gene.
    Holla ØL; Cameron J; Berge KE; Kulseth MA; Ranheim T; Leren TP
    Scand J Clin Lab Invest; 2006; 66(4):317-28. PubMed ID: 16777760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
    Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
    Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.